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Abstract: Cellular gene expression is governed by a complex, multi-faceted network of regulatory interactions. In the last 
decade, microRNAs (miRNAs) have emerged as critical components of this network. miRNAs are small, non-coding 
RNA molecules that serve as post-transcriptional regulators of gene expression. Although there has been substantive pro-
gress in our understanding of miRNA-mediated gene regulation, the mechanisms that control the expression of the miR-
NAs themselves are less well understood. Identifying the factors that control miRNA expression will be critical for further 
characterizing miRNA function in normal physiology and pathobiology. We describe recent progress in the efforts to map 
genomic regions that control miRNA transcription (such as promoters). In particular, we highlight the utility of large-scale 
“-omic” data, such as those made available by the ENCODE and the NIH Roadmap Epigenomics consortiums, for the 
discovery of transcriptional control elements that govern miRNA expression. Finally, we discuss how integrative analysis 
of complementary genetic datasets, such as the NHGRI Genome Wide Association Studies Catalog, can predict novel 
roles for transcriptional mis-regulation of miRNAs in complex disease etiology. 
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INTRODUCTION 
 MicroRNAs (miRNAs) are short (~22 nt) non-coding 
RNAs that regulate gene expression at the post-
transcriptional level. They have been identified as: (i) stable 
plasma biomarkers for various disorders [1], (ii) factors that 
underlie genetic predisposition toward several diseases 
(Sidebar 1), and (iii) promising targets of novel therapeutic 
strategies [2, 3]. Extensive computational and experimental 
research in the last decade has substantially improved our 
understanding of the mechanisms underlying miRNA-
mediated gene regulation [4-7]. However, transcriptional 
control of the miRNAs themselves is poorly characterized, 
and merits further investigation [8-11]. 
 miRNAs are processed from primary transcripts (pri-
miRNAs) that are predominantly transcribed by RNA Po-
lymerase II (Fig. 1). The pri-miRNA harbors one or more 
regions where the underlying sequence folds into a hairpin-
like loop structure, which is referred to as the precursor 
miRNA (pre-miRNA). The pre-miRNA is processed by the 
nuclear Microprocessor Complex, which includes the RNase 
III enzyme Drosha, and exported to the cytoplasm in an en-
ergy-dependent manner. In the cytoplasm, the pre-miRNA is 
cleaved by the endoribonuclease Dicer and its protein part-
ners to yield a ~22bp RNA duplex. Dicer also facilitates the 
incorporation of one of the strands of this duplex, which is 
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the mature miRNA, into the RNA Induced Silencing Com-
plex (RISC). Stable base pairing between a miRNA and a 
target messenger RNA (mRNA) mediates the tethering of the 
RISC to the mRNA. The RISC then employs one or more of 
several strategies to inhibit mRNA translation [5, 12]. 
 The details of this canonical biogenesis pathway (Fig. 1), 
from pri-miRNA to miRNA-RISC, were obtained through 
extensive interdisciplinary biological research during the last 
decade [13]. However, pri-miRNA transcription, which sets 
the entire biogenesis pathway into motion, remained largely 
uncharacterized in large part due to the difficulty of mapping 
miRNA transcription start sites and the immediately up-
stream promoter regions. As is the case for any mRNA tran-
scribed from a protein-coding gene, the 5’-end of a pri-
miRNA corresponds to the active transcription start site 
(TSS). However, due to the rapid rate of pri-miRNA turn-
over (processing and degradation), conventional methods for 
detecting the 5’-end of a transcript (such as cDNA cloning or 
5’-rapid amplification of cDNA ends) are often unproductive 
[14]. Reducing the efficacy of nuclear pri-miRNA process-
ing by knockdown/knockout of the relevant enzymes (such 
as Drosha), thereby increasing the stability of the pri-
miRNA, has helped in some instances [14-17]. However, 
this approach has not been reliable because it induces dra-
matic global down-regulation of mature miRNAs, which can 
lead to diminished cell viability. 
 Several helpful computational strategies for pri-miRNA 
characterization have been developed in the last few years 
[18-24]. Three of the most recent efforts, from Saini et al.
[22]; Wang et al. [23]; and Wang et al. [24], involved com-
prehensive genome-wide scans for known and predicted fea-
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tures of transcription start [22-24] and end regions [22]. 
These in silico analyses offered new predictive insights into 
miRNA promoters and pri-miRNA structure, which provided 
further impetus for large-scale experimental validation in 
diverse cell types. 
Fig. (1). The canonical miRNA biogenesis pathway. (1) RNA 
polymerase II/III transcribes a primary miRNA transcript (pri-
miRNA) which contains one or more hairpin-like structures (pre-
miRNA); (2) The pri-miRNA is processed by a nuclear protein 
complex, liberating a pre-miRNA; (3) The pre-miRNA is exported 
to the cytoplasm; (4) The pre-miRNA is further processed by a 
cytoplasmic protein complex yielding a ~22 nt miRNA duplex; (5)
One strand of the duplex is loaded onto the RNA Induced Silencing 
Complex (RISC), which it guides to target mRNAs for mRNA deg-
radation and/or translational repression. 
 Recent experimental efforts to map miRNA promoters, 
and full-length pri-miRNAs, circumvent the need to access the 
pri-miRNAs themselves, by analysis of specific epige-
nomic/chromatin markers [25]. The basic unit of chromatin is 
the nucleosome, which consists of ~150bp of DNA wrapped 
around an octamer of specialized proteins called histones. His-
tones are subject to a vast array of chemical modifications. 
Combinations of different histone modifications denote differ-
ent classes of functional elements, including promoters (Fig. 
2). These chromatin marks are not directly influenced by pri-
miRNA turnover dynamics; as such, they provide the basis for 
a compelling strategy for the discovery of miRNA promoters. 
EPIGENOMIC DATA ANALYSIS FOR THE DIS-
COVERY OF miRNA PROMOTERS 
 Several recent studies [17, 26-30], including one of our 
own [30], have identified miRNA promoters in different cell 
types by performing genome-wide profiling of promoter-
associated chromatin marks via DNase I hypersensitivity 
(DHS) mapping [31] and chromatin immunoprecipitation 
(ChIP) followed by large-scale microarray analysis 
(DHS/ChIP-chip) or next-generation sequencing (DHS/ 
ChIP-seq)[32]. DHS mapping identifies sites of open chro-
matin that are accessible to factors that influence gene ex-
pression. Active promoters are characterized by open chro-
matin regions enriched for both the histone H3 lysine 4 tri-
methylation (H3K4me3 peaks) and the histone H3 lysine 79 
di-methylation marks (Fig. 2). We recently performed DHS-
seq and ChIP-seq to profile open chromatin, H3K4me3 and 
H3K79me2 across the epigenome of the human pancreatic 
islet [30]. Using these data, which can be downloaded from 
the Gene Expression Omnibus (GEO) repository 
(http://www.ncbi.nlm.nih.gov/geo/) with the accession num-
ber GSE23784, we identified > 10,000 active promoter re-
gions in the human islet [30]. To pinpoint promoters of 
miRNAs from among these, we implemented the following 
five-step strategy (Fig. 3A): 
1) Define the search space as the genomic region between 
the 5’-end of a mature miRNA and the nearest up-
stream RefSeq-annotated transcription start site (TSS); 
2) Scan the space for H3K4me3 peaks; 
3) If one or more are identified, assess each for the pres-
ence of overlapping regions of open chromatin (DHS 
peaks); 
4) Predict promoter orientation based on relative posi-
tioning of the DHS and H3K4me3 peaks. DHS peaks 
tend to be punctate around the TSS, while H3K4me3 
peaks are broader and extend well into the body of the 
transcription unit (Fig. 3A). In a previous analysis of 
known promoters of islet-expressed protein-coding 
genes [30], we found that the location of the DHS 
peak relative to the H3K4me3 peak predicts the orien-
tation/directionality of the underlying promoter with 
~90% accuracy; 
5) Finally, if the predicted orientation matches that of the 
mature miRNA, assess whether the signal for histone H3 
lysine 79 dimethylation (H3K79me2), which denotes ac-
tively transcribed regions, extends from the H3K4me3 
peak to at least the 3’-end of the mature miRNA.
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Fig. (2). Epigenomic profiling. Specific combinations of chromatin marks denote different classes of functional elements, including poised 
enhancers, active enhancers, transcribed loci, and promoters. For example, promoters are enriched for H3K4me3, H3K27ac, and H3K79me2; 
active enhancers are depleted for H3K4me3 and enriched for H3K27ac. 
Fig. (3). (A) miRNA promoter identification using epigenomic profiles. (1) Define the search space as the genomic region between the 5’ 
end of a mature miRNA and the nearest RefSeq annotated transcription start site (TSS), (2) Scan for H3K4me3 peaks, (3) If one or more are 
identified, assess each for the presence of overlapping DHS peaks, (4) Apply the “strand predictor” algorithm to assign an orientation to the 
H3K4me3 peak, (5) If this predicted orientation matches that of the mature miRNA, assess whether the H3K79me2 signal extends from the 
H3K4me3 peak to at least the end of the mature miRNA. If so, then the DHS peak will be designated as the candidate TSS for the mature 
miRNA in consideration. (B) Candidate islet-active TSS for the primary transcript of the widely-expressed let-7a-1/7d/7f-1 miRNA 
cluster. The TSS (green box; DHS+, H3K4me3+, H3K4me1-) is ~10kb upstream of the 5’-most microRNA in the cluster (red box), and the 
full-length primary transcript (H3K79me2+) of ~35kb matches a known expressed sequence tag (EST BSG326593). This EST likely repre-
sents a non-coding RNA transcript from which the let-7 miRNAs are processed. 
 This approach identified novel promoter regions (i.e. not 
previously annotated and not shared with a protein-coding 
gene) for ~50 pri-miRNAs in human pancreatic islets (Table 
1; Fig. 4). These included: (1) 37 that overlapped computa-
tionally predicted transcription start sites according to 
Eponine [33]; (2) 16 that corresponded to start sites of anno-
tated expressed sequence tags (ESTs) (e.g. Fig. 3B); and (3) 
5 of 8 previously mapped pri-miRNA promoters, such as the 
one for pri-miR-21[34]. The average distance between an islet 
pri-miRNA promoter and the nearest (5’-most) mature 
miRNA sequence within the pri-miRNA is ~35kb. Many 
miRNAs appear to be very near to their promoters; for in-
stance, the islet-enriched miRNAs miR-200c, miR-375, and 
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promoters. Other miRNAs with important biological functions 
in the islet, such as miR-30e and miR-29b, are much further 
from their promoter (~45kb and ~65kb, respectively). Perhaps 
the most striking and unexpected finding was that miR-
876/873 is ~325kb downstream of its promoter (Fig. 4). This 
finding is supported by ESTs from human brain and pancre-
atic islet tissue. 
 The application of epigenomic strategies similar to the one 
described above in other human and mouse cell types has led 
to a comprehensive set of annotations for mammalian miRNA 
promoters [35], several of which have been validated by inde-
pendent experiments [27, 28]. For example, Ozsolak et al. [27] 
performed ChIP-chip screens for H3K4me3, H3K9/14ac, 
RNA Polymerase II, and RNA Polymerase III in the genomic 
regions 20kb upstream and 1kb downstream of miRNAs in 
two melanoma cell lines and one breast cancer cell line. Their 
method accurately detected the few miRNA promoters that 
had been previously determined by 5’ rapid amplification of 
cDNA ends (RACE), including those for miR-146a, miR-
146b, miR-155, and miR-21. They also additionally verified 
six novel miRNA promoters by promoter cloning and reporter 
gene assays. In another study, Barski et al. [28] performed 
ChIP-seq based profiling of eight histone methylation marks, 
including H3K4me3 and H3K79me2, to identify miRNA 
promoters in CD4+ T cells. They reported 85 miRNA promot-
ers that are not shared with a protein-coding gene, among 
which >40% have ESTs that start at the predicted promoter 
and extend beyond the miRNA locus. They also additionally 
validated six novel miRNA promoters by 5’ RACE as well as 
by promoter cloning and reporter gene assays. 
 Most of the published epigenomic strategies for miRNA 
promoter identification are based on only three or four types of 
chromatin marks; however, there are over 100 known distinct 
histone modifications [36]. Recently, a computational biology 
group at the Massachusetts Institute of Technology used a mul-
tivariate Hidden Markov Model (HMM) to analyze previously 
published genome-wide profiles for 38 histone modifications in 
human T cells and defined 51 ‘chromatin states’ that correspond 
to specific functions, including several stages of promoter activ-
ity and transcription [37]. As similarly comprehensive epige-
nomic datasets become available for additional cell types, the 
HMM-based tool (ChromHMM) can be applied not only to 
identify high-confidence miRNA promoters, but also other 
types of regulatory elements (e.g. long-range enhancers or si-
lencers) that likely contribute to miRNA transcription. 
 It is important to note that while the H3K4me3 mark is 
generally associated with promoters, it is not enriched at some 
non-constitutively active promoters [38]. To account for this, 
alternative strategies for promoter identification have emerged 
recently [39], including high-throughput sequencing of nas-
cent RNA, which provides a snapshot of genome-wide tran-
scriptional activity [40]. For example, an HMM was applied to 
nascent RNA-seq data from MCF-7 cells to determine the full-
length primary transcripts of all expressed miRNAs and to 
assess which of these are regulated by estradiol [41].  
RELEVANT GENOMIC DATA REPOSITORIES 
microRNA Genomics 
 The official database of microRNAs, miRBase 18.0 [42], 
offers information on miRNAs in 168 different species. Cur-
rently, miRBase lists 1,921 mature human miRNAs. For 
each miRNA, miRBase provides the RNA sequence, ge-
nomic location (chromosomal coordinates), genomic context 
(overlapping genes), experimental evidence including data 
from high-throughput small RNA sequencing, and links to 
databases that list computationally predicted and/or empiri-
cally validated target genes. Despite the improvements 
brought about by high-throughput sequencing technology, 
accurate miRNA discovery remains technically challenging. 
As such, some sequences listed as candidate miRNAs in 
miRBase could represent other non-miRNA-related small 
RNA products (functional or not)[43]. Nonetheless, miR-
Base remains the most reliable, widely used and regularly 
updated database for miRNA-related information. Other re-
lated resources include miRGen, microRNA.org, miR-
NAMap, mimiRNA, TransmiR, miReg, and miRStart (see 
“Resource List”). 
The Epigenome 
 The NHGRI-funded Encyclopedia of DNA elements 
(ENCODE) Consortium and the NIH Roadmap Epigenomics 
Consortium manage repositories of genome-wide profiles of 
various types of biological data across a broad set of cell 
types and primary tissues. 
 At the present time, the Roadmap project has generated 
epigenomic data for 61 different cell/tissue types, with a par-
ticular focus on chromatin marks, including open chromatin, 
DNA methylation, and a variety of histone modifications. 
While not all of the different types of data are available for 
all of the cell types, epigenome-wide data for the following 
six histone modifications are available for all 61 cell types: 
H3K4me1, H3K4me3, H3K9me3, H3K27ac, H3K27me3, 
and H3K36me3. These histone modifications are referred to 
by the Roadmap project as the “core” set, and their relevance 
to chromatin structure and gene expression has been exten-
sively discussed in several previous review articles. The 
Roadmap data can be visualized on and downloaded from 
numerous websites (see “Resource List”), including the 
Roadmap Browser, the Human Epigenome Atlas, the Na-
tional Center for Biotechnology Information (NCBI) Epige-
nome Gateway, or the USCS Epigenome Browser. For fur-
ther details on the Roadmap data resource, readers are di-
rected to [44]. 
 Currently, the ENCODE project has generated a diverse 
array of genomic information, including various epigenomic 
marks, transcription factor binding events, RNA-protein in-
teractions, small RNA expression, mRNA expression, and 
three-dimensional chromatin structure, across ~150 different 
cell/tissue types. Although the scope of the ENCODE project 
is substantially broader than that of the Roadmap project, the 
number and types of data sets available across the different 
cell types is much more variable. For example, ENCODE 
has generated 335 different datasets for K562 cells (includ-
ing 224 transcription factor and histone modification ChIP-
seq datasets), but only 12, 4, and 2 datasets for human em-
bryonic kidney 293 (HEK293) cells, primary hepatocytes, 
and human pulmonary artery endothelial cells (HPAEC), 
respectively. The data from the ENCODE Consortium is 
available for download directly from their website (http://en 
codeproject.org) and can be mined using the tools at the
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Table 1. Independent Promoter Regions for microRNAs in the Human Islet. Chromosomal Coordinates of Promoter Regions 
(TSS-500, TSS+1000) for ~50 pri-microRNAs in Independent Transcription Units Are Shown.  The TSS is Defined As the 
Peak Point of the DNase I Hypersensitivity (DHS) Peak.  For Every miRNA Cluster in the pri-miRNA, One Representa-
tive miRNA is Listed 
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(Table 1) contd…. 















Fig. (4). miRNA promoters in human pancreatic islets. Promoter regions were identified for 50 pri-miRNAs (red data points). Y-axis de-
picts the distance (base pairs; bp) between the identified promoter and the 5’-most mature miRNA in the pri-miRNA. Blue dashed line depicts 
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University of California at Santa Cruz (UCSC) Table 
Browser (see “Resource List”). For further details on the 
ENCODE project and related datasets, readers are directed to 
the Nature ENCODE Explorer (http://www.nature.com/ en-
code) and the OpenHelix ENCODE Tutorial (http://www. 
openhelix.com/ENCODE). 
 Several tools, including RegulomeDB [45] and HaploReg 
[46], have been developed to map human genetic variants 
onto predicted regulatory elements as determined by integra-
tive analysis of epigenomic data from the ENCODE and 
Roadmap projects [47]. These resources will be instrumental 
for characterizing functional elements that control miRNA 
transcription as well as for developing hypotheses regarding 
the molecular mechanisms underlying disease-associated 
genetic loci. 
Disease-Associated Genetic Variants 
 The NHGRI Genome Wide Association (GWA) Studies 
Catalog provides a centralized resource for Disease/trait-
Associated Single nucleotide polymorphisms (DASs). As of 
June 2012, the catalog includes 1,271 GWA studies report-
ing 6,446 DASs, and the list is rapidly growing. Recent bio-
informatic analyses of these data revealed that DASs are 
enriched in genomic regions that regulate gene expression 
[48, 49], particularly gene promoters [50]. Because changes 
in miRNA expression patterns have been previously corre-
lated with a number of different phenotypes and disease out-
comes [51], it is likely that DASs also occur in miRNA pro-
moters. As more miRNA promoters are identified, they can 
be cross-referenced with DAS data from the GWAS Catalog 
in order to assess potential roles for transcriptional mis-
regulation of miRNAs in complex disease etiology. For addi-
tional databases related to disease-associated genetic vari-
ants, see “Resource List”. 
CONCLUSION 
 miRNAs have emerged as important regulators of gene 
expression. While research in the area of miRNA-mediated 
gene regulation has blossomed in the last decade, the factors 
that regulate miRNA expression have remained elusive, in 
part due to the challenge of identifying regulatory elements 
that control miRNA transcription. However, the latest ad-
vances in genome technology and chromatin biology are 
enabling systematic functional annotation of the human ge-
nome, thereby shedding light on the previously obscured 
world of miRNA transcription. 
 Many large-scale efforts are currently underway to cata-
log epigenomic profiles of chromatin marks in a diverse ar-
ray of cell types, in both normal and perturbed states. These 
databases represent rich resources for biological discovery. 
Integrative analysis of the data with tools such as 
ChromHMM will expand our knowledge base of functional 
regions of the genome, including miRNA promoters. As epi-
genomic data becomes available for a wider range of physio-
logical conditions, it will be increasingly possible to investi-
gate the plasticity of miRNA promoters. 
 Because a single miRNA can fine-tune the expression of 
hundreds to thousands of genes in numerous biological 
pathways, the mis-expression of miRNAs themselves likely 
underlies many inherited disorders. The recent GWAS find-
ing that variants near miR-137 are implicated in schizophre-
nia is likely to be only the ‘tip of the iceberg’. As more 
miRNA promoters are identified, genetic variants that occur 
within them can be cross-referenced with a growing number 
of databases that provide information on disease-associated 
genetic loci. 
SIDEBAR 1: miRNA-RELATED GENETIC VARIANTS 
AND HUMAN DISEASE 
 miRNA-related cis-regulatory genetic variants (GVs) can 
occur within four categories: (1) mature miRNAs, (2) pre-
miRNAs, (3) pri-miRNAs, or (4) miRNA transcriptional 
control elements (such as promoters). Population genomic 
analyses have demonstrated strong purifying selection on the 
first two functional categories, implying that GVs in mature 
miRNAs and pre-miRNAs are likely to be deleterious and 
could lead to disease [52, 53]. Several examples have been 
reported in the last few years, including a GV in pre-miR-16 
that is associated with chronic lymphocytic leukemia [54] 
and two GVs, one in pre-miR-96 and the other in mature 
miR-96, that cause hearing loss [55, 56]. Until recently, the 
search for disease-associated GVs within categories 3 and 4 
has been greatly impeded by a lack of well-defined annota-
tions for these elements. One interesting case, which illus-
trates the potential impact of these categories of GVs, is that 
of a functional variant in the promoter of miR-146a [57] that 
confers significant risk for systemic lupus erythematosus 
[58]. 
 A recent genome-wide association study of schizophrenia 
was the first large human population based study to report 
the significant association of a common single nucleotide 
polymorphism (SNP) at a miRNA locus (miR-137) with a 
complex disease [59]. Complex diseases such as schizophre-
nia are increasingly viewed as “network disorders”[60]. This 
makes it extremely challenging to identify disease-causing 
GVs in single genes, because biological networks encode 
mechanisms for conferring robustness against perturbations 
to individual genes within the network. Network robustness 
is imparted, in large part, by a web of miRNA activity [61]; 
as such, genetic perturbations of miRNAs will likely have a 
dramatic effect on network output. Therefore, it is expected 
that as more high-powered genetic association studies are 
performed, an increasing number of miRNA-related GVs 
will be implicated in complex disease etiology. 
 Several databases and web servers have been developed 
to facilitate data mining of GVs in miRNA-related genomic 
regions, including Patrocles, dbSMR, PolymiRTS, MicroS-
NiPer, miRdSNP, and dPORE-miRNA (see “Resource 
List”).
RESOURCE LIST 
 Listed below are a few databases/web servers of rele-
vance to this article’s discussion of microRNA genomics: 
microRNA Genomics 
• miRBase: http://www.mirbase.org/ 
• miRGen: http://diana.cslab.ece.ntua.gr/mirgen/ 
• miRNAMap: http://mirnamap.mbc.nctu.edu.tw/ 





• miReg: http://www.iioab-mireg.webs.com/ 
• TransmiR: http://202.38.126.151/hmdd/mirna/tf/ 
• miRStart: http://mirstart.mbc.nctu.edu.tw/ 
Epigenomic Data 
• ENCODE project: http://encodeproject.org 
• UCSC Table Browser: http://genome.ucsc.edu/cgi-bin/ 
hgTables 
• Nature ENCODE Explorer: http://www.nature.com/en-
code 
• UCSC Epigenome Browser: www.epigenomebrowser. 
org
• Roadmap Epigenomics Browser: www.roadmapepigeno 
mics.org 
• The Human Epigenome Atlas: http://www.genboree.org/ 
epigenomeatlas 
• NCBI Epigenome Gateway: http://www.ncbi.nlm.nih.gov 
/epigenomics 
• RegulomeDB: http://regulome.stanford.edu/ 
• HaploReg: http://www.broadinstitute.org/mammals/haplo 
reg/haploreg.php 
Disease-Associated Genetic Variants 
• NHGRI GWAS Catalog: http://www.genome.gov/gwa 
studies/ 
• GWAS Integrator: http://hugenavigator.net/HuGENaviga 
tor/gWAHitStartPage.do 
• GWASdb: http://jjwanglab.org:8080/gwasdb/ 
• OMIM: http://www.ncbi.nlm.nih.gov/omim 
miRNA-Related Genetic Variants 
• Patrocles: http://www.patrocles.org/ 
• dbSMR: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 
2676258/ 
• PolymiRTS: http://compbio.uthsc.edu/miRSNP/ 
• MicroSNiPer: http://cbdb.nimh.nih.gov/microsniper/ 
• miRdSNP: http://mirdsnp.ccr.buffalo.edu/ 
• dPORE-miRNA: http://cbrc.kaust.edu.sa/dpore/ 
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ABBREVIATIONS 
ChIP = Chromatin immunoprecipitation 
DAS = Disease-Associated Single Nucleotide 
Polymorphism 
DHS = DNase I Hypersensitivity Site 
ENCODE = Encyclopedia of DNA Elements 
GV = Genetic Variant 
GWAS = Genome-Wide Association Study 
H3K4me1 = Histone H3 lysine 4 Mono-methylation 
H3K4me3 = Histone H3 lysine 4 tri-Methylation 
H3K27ac = Histone H3 lysine 27 Acetylation 
H3K36me3 = Histone H3 lysine 36 tri-Methylation 
H3K79me2 = Histone H3 lysine 79 di-methylation 
H3K9me3 = Histone H3 lysine 9 tri-Methylation 
H3K27me3 = Histone H3 lysine 27 tri-Methylation 
HMM = Hidden Markov Model 
HPAEC = Human Pulmonary Artery Endothelial 
Cells 
K562 = Human Myelogenous Leukemia Cell Line 
MCF-7 = Michigan Cancer Foundation-7 Breast 
Cancer Cell Line 
miRNA = microRNA 
pre-miRNA = miRNA Precursor 
RACE = Rapid Amplification of cDNA Ends 
RISC = RNA Induced Silencing Complex 
SNP = Single Nucleotide Polymorphism 
TSS = Transcription Start Site 
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